A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT03466567
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
The aim of the study is to investigate the effect of the medicines, probenecid and ciclosporin on the concentrations of SNAC. SNAC is an ingredient of the semaglutide tablets. Participants will get 3 different treatments (that is 3 treatment periods): 1) a single dose of 3 mg semaglutide, 2) a single dose of 600 mg ciclosporin with 3 mg semaglutide, 3) 500 mg probenecid twice a day for 3 ½ days with a single dose of 3 mg semaglutide on the last day.
The sequence of treatments participants get is decided by chance. Probenecid and ciclosporin are available medicines. They are given by doctors. Semaglutide contains SNAC. It cannot be prescribed yet.
The study will last for up to 125 days. Participants will have 17 to 18 visits at the study centre. This includes short visits at the centre for blood sampling only. Participants will have several blood draws.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
- Male or female of non-childbearing potential, aged 18-64 years (both inclusive) at the time of signing informed consent.
- Body mass index between 18.5 and 29.9 kg/sqm (both inclusive).
- Body weight greater than or equal to 50.0 kg.
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
- Use of tobacco and nicotine products, defined as: A. Smoking more than 1 cigarette or the equivalent per day B. Not able or willing to refrain from smoking and use of nicotine substitute products during the in-house period(s).
- Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
- History (as declared by the subject) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).
- Known glucose-6-phosphate-dehydrogenase deficiency (as declared by the subject).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Ciclosporin, probenecid, oral semaglutide Ciclosporin Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3. Oral semaglutide, ciclosporin, probenecid Semaglutide Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3. Ciclosporin, probenecid, oral semaglutide Semaglutide Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3. Oral semaglutide, ciclosporin, probenecid Probenecid Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3. Oral semaglutide, ciclosporin, probenecid Ciclosporin Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3. Probenecid, oral semaglutide, ciclosporin Semaglutide Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3. Probenecid, oral semaglutide, ciclosporin Ciclosporin Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3. Probenecid, oral semaglutide, ciclosporin Probenecid Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3. Ciclosporin, probenecid, oral semaglutide Probenecid Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
- Primary Outcome Measures
Name Time Method Cmax,SNAC,SD, maximum observed SNAC plasma concentration on the concentration-time curve after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC activity measured in blood.
AUC0-tz,SNAC,SD, area under the SNAC plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC activity measured in blood.
- Secondary Outcome Measures
Name Time Method AUC0-tz,E506,SD, area under the SNAC metabolite E506 plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E506 activity measured in blood.
AUC0-tz,E494,SD, area under the SNAC metabolite E494 plasma concentration-time curve from time 0 to time of the last quantifiable concentration after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E494 activity measured in blood.
Cmax,E494,SD, maximum observed SNAC metabolite E494 plasma concentration on the concentration-time curve after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E494 activity measured in blood.
AUC0-∞,E1245,SD, area under the SNAC metabolite E1245 plasma concentration-time curve from time 0 to infinity after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E1245 activity measured in blood.
AUC0-∞,E1246,SD, area under the SNAC metabolite E1246 plasma concentration-time curve from time 0 to infinity after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E1246 activity measured in blood.
Cmax,E506,SD, maximum observed SNAC metabolite E506 plasma concentration on the concentration-time curve after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E506 activity measured in blood.
Cmax,E1245,SD, maximum observed SNAC metabolite E1245 plasma concentration on the concentration-time curve after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E1245 activity measured in blood.
AUC0-∞,E1247,SD, area under the SNAC metabolite E1247 plasma concentration-time curve from time 0 to infinity after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E1247 activity measured in blood.
Cmax,E1247,SD, maximum observed SNAC metabolite E1247 plasma concentration on the concentration-time curve after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E1247 activity measured in blood.
Cmax,E1246,SD, maximum observed SNAC metabolite E1246 plasma concentration on the concentration-time curve after a single dose of oral semaglutide 0-48 hours Calculated based on plasma SNAC metabolite E1246 activity measured in blood.
Trial Locations
- Locations (1)
Novo Nordisk Investigational Site
🇩🇪Berlin, Germany